Travere Therapeutics, Inc. (TVTX)

Market Cap	1.47B
Revenue (ttm)	233.18M
Net Income (ttm)	-321.55M
Shares Out	88.74M
EPS (ttm)	-4.08
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,214,412
Open	16.48
Previous Close	17.94
Day's Range	15.99 - 17.26
52-Week Range	5.12 - 25.29
Beta	0.84
Analysts	Strong Buy
Price Target	33.08 (+99.76%)
Earnings Date	May 5, 2025

About TVTX

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company’s products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urin...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 385
• Stock Exchange: NASDAQ
• Ticker Symbol: TVTX
• Website: https://www.travere.com

Financial Performance

In 2024, Travere Therapeutics's revenue was $233.18 million, an increase of 60.55% compared to the previous year's $145.24 million. Losses were -$321.55 million, 188.6% more than in 2023.

Analyst Forecast

According to 13 analysts, the average rating for TVTX stock is "Strong Buy." The 12-month stock price forecast is $33.08, which is an increase of 99.76% from the latest price.

Price Target

$33.08

(99.76% upside)

Analyst Consensus: Strong Buy